BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Policy

  CureVac, BioNTech Enter Legal Battle Over mRNA Vaccine Technology

  CureVac has filed a lawsuit against BioNTech and two of its subsidiaries for allegedly infringing on its intellectual property rights over mRNA technology used in the COVID-19 vaccine.

  July 6, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Researchers Explain Risks of COVID-19 Re-Infection

  Findings from a study support the claim that the risk of developing a serious issue, such as respiratory or cardiac issues, is much more probable in the first 30 days following infection from COVID-19.

  July 6, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano
• 

  Study Suggests Time-Restricted Feeding Could Be Key to Combat Obesity

  A new study on gut microbiome activity suggests that diet and eating schedules may affect the body’s propensity to become obese and unhealthy.

  July 6, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Global Roundup: Astellas, Mogrify Battle Sensorineural Hearing Loss & More

  Mogrify and Astellas have forged a collaboration surrounding in vivo regenerative medicine approaches, while CardiNor inked a distribution deal with IBL-America.

  July 6, 2022

   · 

  5 min read

   · 

  Alex Keown
• 

  Business

  The Platform that Keeps on Giving: the AstraZeneca/TeneoTwo Deal

  BioSpace caught up with Roland and Ben Buelow of Ancora, and Lightspeed Venture Partners’ Galym Imanbayev to talk about the AstraZeneca deal and the company’s unique business model.

  July 6, 2022

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Drug Development

  Eisai, Biogen Score Priority Review on Another Alzheimer’s Hopeful

  Eisai and Biogen’s BLA for lecanemab for Alzheimer’s disease received FDA Priority Review with a target action date of January 6, 2023, while Roche’s lymphoma drug scored the same designation.

  July 6, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Applied Molecular Transport’s UC Candidate Proves Effective in Early-Stage Intervention

  In patients stricken with ulcerative colitis for less than five years, AMT-101 was nearly three times more effective in inducing clinical remission than the placebo after eight weeks.

  July 6, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Policy

  Coherus, Junshi’s Cancer Checkpoint Inhibitor Gets Second Chance with FDA

  A cancer drug co-developed by Coherus BioSciences and Junshi Biosciences, toripalimab, is getting another opportunity before the U.S. Food and Drug Administration.

  July 6, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Sarepta, Roche Tout Promising Data for Muscular Dystrophy Gene Therapy

  Sarepta Therapeutics and its partner, Roche, presented promising functional data from several trials of its gene therapy for Duchenne muscular dystrophy.

  July 6, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  Veru, Immunome Tout Positive Data for COVID-19 Therapeutics

  Veru Inc. has announced the publication of positive Phase III results from its COVID-19 antiviral therapeutics that could lead to potential Emergency Use Authorization.

  July 6, 2022

   · 

  3 min read

   · 

  Alex Keown